Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S

Published: Thursday, May 16, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
TriLink BioTechnologies, Inc. announced that it has signed a licensing agreement with QuantiBact A/S to offer twisted intercalating nucleic acid (TINA) modified oligos.

TINA molecules are intercalators placed at the 5’ end of primers to stabilize duplex formation. Their unique properties improve the sensitivity and specificity of endpoint and real-time PCR. TINA may find applications wherever an enhanced Tm is required such as triplex formation or potentially even gene silencing.

“At QuantiBact we strive to make our technologies available throughout the research and diagnostic communities. We appreciate being able to work with dedicated companies that hold high recognition in the market place. The market position as well as in depth knowledge of nucleic acids embedded within TriLink will enable us to further reach our goal,” says Palle Schelde, CEO, Managing Director, QuantiBact.

“At TriLink we pride ourselves on our quality and our ability to handle unique nucleic acid modifications. This makes us an ideal manufacturer of TINA oligos,” stated Richard Hogrefe, Ph.D., President and CEO of TriLink. “We are excited to work with the great folks at QuantiBact and see how this technology might advance molecular diagnostics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TriLink to Open New Early Phase Therapeutic Manufacturing Facility
Company's new 2,000 square foot diagnostic and pharmaceutical GMP production facility will be fully operational July 2014.
Tuesday, May 27, 2014
TriLink Announces New License Agreement with Biofortuna
Agreement for use of CleanAmp™ dNTPs in Biofortuna’s freeze-drying contract development and production service.
Friday, November 08, 2013
TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S
TriLink BioTechnologies Inc. announced that it has signed a licensing agreement with QuantiBact A/S to offer twisted intercalating nucleic acid (TINA) modified oligos.
Thursday, May 09, 2013
TriLink BioTechnologies, Inc. Awarded European Patent
TriLink BioTechnologies, Inc. announces the award of their CleanAmp™ Primer patent by the European Patent Office (EPO Patent no. 2032714).
Tuesday, May 31, 2011
TriLink BioTechnologies, Inc. Announces License Agreement with Biofortuna Ltd
TriLink BioTechnologies, announced that it has signed a licensing agreement with Biofortuna Ltd. for use of CleanAmp™ dNTPs in Biofortuna’s freeze dried in vitro diagnostic PCR kits.
Tuesday, September 14, 2010
TriLink Awarded SBIR Phase II Grant: Chemical Determinants of DNA Ligase Fidelity
The National Institutes of Health recently awarded TriLink BioTechnologies, Inc. (TriLink) a Phase II SBIR Grant of approximately $725,000 to continue their work on developing reagents to enhance the specificity of DNA ligase.
Tuesday, June 22, 2010
TriLink BioTechnologies, Inc. Announces Supply Agreement with ETS Laboratories
TriLink BioTechnologies, Inc. (TriLink) announced that it has signed an agreement with ETS Laboratories (ETS) to supply CleanAmp™ dNTPs for use in their Scorpions™ Wine Spoilage Detection System.
Tuesday, April 27, 2010
Scientific News
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
OncoCyte, The Wistar Institute Enter Global Licensing Agreement
Exclusive rights to commercialize biomarker assay follows years of positive collaboration on lung cancer diagnostic test.
Easier Diagnosis for Fungal Infection of the Lungs
A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.
Antibiotic Susceptibility Testing
A team of biologists and biomedical researchers at UC San Diego has developed a new method to determine if bacteria are susceptible to antibiotics within a few hours, an advance that could slow the appearance of drug resistance and allow doctors to more rapidly identify the appropriate treatment for patients with life threatening bacterial infections.
Mitochondrial Troublemakers Unmasked in Lupus
Drivers of autoimmune disease inflammation discovered in the traps of pathogen-capturing white blood cells.
DNA Analysis in the Fast Lane
Rice bioengineers' method should lead to better database of thermal behaviors.
‘Simple Rules’ Calculate Ovarian Cancer Risk
Scientists have formulated a system that uses ultrasound images to accurately work out the likelihood of an ovarian growth being cancerous.
Finding the Needle in a Microbial Haystack
After developing a novel investigational technology called PathoChip that can rapidly identify elusive microorganisms, a team of Penn Medicine researchers recently succeeded for the first time in identifying a pathogen in a patient sample, demonstrating the proof of principle that this technology can be used to identify pathogens in human disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!